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Cancer immunotherapy with antibodies targeting immune
checkpoints has demonstrated durable clinical benefit,
though responses have not been universal and, in particu-
lar, not effective for tumors lacking preexisting lymphocy-
tic infiltration. Oncolytic viruses (OV) have recently
emerged as an important addition to the immunotherapy
armamentarium, with promising activity seen in recent
clinical trials. To test whether the inflammatory responses
activated by OV could be harnessed to drive therapeutic
efficacy of immunomodulatory antibodies in poorly-
inflamed tumors, we employed poorly immunogenic ani-
mal tumor models, including the transplantable B16-F10
and TRAMP C2 tumors and genetically-engineered
BRAFV600EPTENfl/fl melanoma. As a model OV, we used
Newcastle Disease Virus (NDV), an avian virus that was
previously demonstrated to be a strong activator of type I
interferon and DC maturation. Administration of NDV to
a single tumor in animals bearing bilateral flank tumors
concomitant with adoptive transfer of naïve transgenic
antigen-specific CD4 or CD8 lymphocytes led to efficient
infiltration of bilateral tumors with the adoptively-trans-
ferred cells, an effect that was not seen in the absence of
virus treatment or when heterologous tumors were used
on both flanks. Consistent with these findings, therapy
with NDV in the absence of adoptive T cell transfer
resulted in lymphocyte infiltration and tumor growth
delay in both virus-injected and distant tumors in all
tumor models. Therapy with NDV was associated with
upregulation of PD-L1 on tumor cells and tumor-infiltrat-
ing innate and adaptive immune cells in both virus-
injected and distant tumors, an effect that was in part
mediated by type I IFN produced during viral infection.
Notably, combination therapy with localized NDV and
systemic blockade of PD-1, PD-L1, or CTLA-4 led to
rejection of the majority of both virus-injected and distant
tumors in the B16-F10 and TRAMP C2 models and signif-
icant tumor growth delay in the BRAFV600EPTENfl/fl
model. This effect was associated with marked tumor infil-
tration with activated effector, but not regulatory T cells,
and was abrogated with CD8 or IFN-g depletion or in
IFNAR-/- mice. These results demonstrate that in poorly-
immunogenic cancers lacking TIL infiltration, therapy
with oncolytic viruses such as NDV can convert the
tumors to an inflamed phenotype in absence of virus
spread to all tumor sites, resulting in potentiation of thera-
peutic efficacy of antibodies targeting immune check-
points. These findings provide a rationale for further
exploration of such combination strategies, and trials
using different OVs are currently in development to test
this concept in clinic.
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